News Center

News Center

News Center

DualityBio Announces 2026 Interim Results and Corporate Updates

2026-08-28

DualityBio Enters a Global Collaboration and License Agreement with Genentech to Develop Next-Generation ADCs Built on DualityBio's DUPAC Novel-Payload Platform
2026-08-25

DualityBio’s ADAM9 ADC DB-1317 Granted FDA Fast Track Designation for the Treatment of Advanced Pancreatic Ductal Adenocarcinoma
2026-08-20

DualityBio and BioNTech to Highlight First Global Data of Pumitamig/Elfetabart Drozuntecan Novel-Novel Combination in Lung Cancer at WCLC 2026
2026-07-28

DualityBio and BioNTech’s B7-H3 ADC Elfetabart Drozuntecan Granted China NMPA Breakthrough Therapy Designation for Metastatic Castration-Resistant Prostate Cancer
2026-07-20

DualityBio and BioNTech to showcase new data for B7-H3 ADC Elfe-D and HER3 ADC DB-1310 at the 2026 ESMO Congress
2026-06-15

DualityBio’s STAR Market IPO Application Officially Accepted by the Shanghai Stock Exchange

«
1
2
3
4
5
6
7
»

Scan the code to follow DualityBio official wechat

Phone：021-2601 8730

Address：Full floor, 11th floor, tower a, Datang International Plaza,China

Construction Engineering Group, No. 868 Yinghua Road, Pudong New Area, Shanghai